Gastric Cancer Therapy Market | Recognizing and Managing Fragmentation of Care and Evidence Gaps | Top Key Players: BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, F. HOFFMANN-LA ROCHE, GLAXOSMITHKLINE, IMUGENE LIMITED

The global gastric cancer therapy market is expected to register a CAGR of 13.0% during the forecast period (2018 - 2023). Asia Pacific dominates the market, due to the growing incidence of gastric cancer in that region.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16965
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Growing Incidence of Gastric Cancer
According to a report published by Indian Council of Medical Research in 2014, gastric cancer is the fourth leading cancer in the world, accounting for 736,000 deaths. Around 1 million new cases of gastric cancer and 0.7 million deaths due to gastric cancer are reported every year. Age-standardized incidence rates are approximately twice as high in men as in women. Presently, gastric cancer is more common in Asia, than in the United States or Europe. Notably, 42% of cases occur in China alone.
Thus, increasing incidence of gastric cancer, coupled with strong drug pipeline, and introduction of novel therapies for metastatic stomach cancer, across the world, are likely to drive the market for gastric cancer therapy.

Key Developments in the Market
• February 2018: Imugene, an immune oncology company announced that its cancer vaccine yields promising results in gastric cancer clinical trial studies.
• September 2017: The Food and Drug Administration (FDA) approved the immunotherapy drug pembrolizumab(Keytrudau00ae) to be used on patients with advanced gastric (stomach) cancer.

Major Players:
BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, F. HOFFMANN-LA ROCHE LTD, GLAXOSMITHKLINE PLC, IMUGENE LIMITED, MERCK KGAA, NOVARTIS AG, ONO PHARMACEUTICALS, OTSUKA HOLDINGS CO. LTD, AND SANOFI amongst others.

Get Quality Discount @ https://marketprognosis.com/discount-request/16965
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

High Cost of Cancer Therapy and Side Effects of Cancer Drugs
The global cost of cancer therapy and drugs increased from USD 91 billion to USD 113 billion, in 2016. High cost of therapy and adverse events associated with the existing cancer drugs, for treatment of stomach cancer, may hinder the global stomach cancer market. The serious side effects associated with the usage of drugs include autoimmune reactions and infusion reactions. Additionally, a large patient pool undiagnosed with gastric cancer and the lack of awareness regarding gastric cancer are likely to impede the growth of the global cancer therapy market.

Asia-Pacific to Dominate the Market
Asia-Pacific dominates the global gastric cancer therapy market, owing to high incidence of stomach cancer in that region. China is expected to show a tremendous growth for this market, during the forecast period, owing to factors, such as high prevalence of obesity, and growing awareness about diabetes care. The growing incidence of gastric cancer in China is followed by Japan and Korea. China accounts for over 40% of all new gastric cancer cases in the world, which will drive the market for gastric cancer therapy in China.

Browse Report @ https://marketprognosis.com/enquiry/16965
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMarkPvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.